S920
Clinical - Mixed sites & palliation
ESTRO 2026
Intermediate response and pain progression were considered as no response. In this analysis pain response rate at five and nine weeks was compared between the esophagus-sparing and standard- treatment arms. Univariate logistic regression was performed to adjust for potential confounders, including gender, age, baseline opioid use (> 60 mg oral morphine equivalent/day), performance status (0– 1 vs. 2–4), baseline pain score (0–5 vs. 6–10), radiation dose (8–10 Gy/1 fx vs. 25 Gy/5 fx and 30 Gy/10 fx), and PTV coverage (PTV V90 covered by 100 % of the prescribed dose: yes/no). Results: One hundred patients completed baseline pain assessment and at least one follow-up. All patients received oral prednisone (50–150 mg). Baseline characteristics were well balanced, Table 1. Thirty patients were excluded from analysis due to a baseline pain score of 0 (18 in the esophagus-sparing arm, 12 in the standard arm). . Five weeks pain response rates were 39% and 46% in the standard arm and esophagus-sparing arm respectively ( χ² p = 0.56), Figure 1. Nine weeks pain response rates were 48% and 57% in the standard arm and esophagus-sparing arm respectively ( χ² p = 0.47).
Conclusion: The PTV compromise introduced to achieve esophageal sparing did not result in inferior pain response compared with standard radiotherapy. One- third of patients presented with a baseline NRS score of 0; we speculate that this early pain relief is due to
Made with FlippingBook - Share PDF online